Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 May 8;123(19):2906-7.
doi: 10.1182/blood-2014-04-565515.

Abnl(17p) in AML: who will guard the guardian?

Minoo Battiwalla  1
Affiliations
Comment

Abnl(17p) in AML: who will guard the guardian?

Minoo Battiwalla. Blood. .

Abstract

In this issue of Blood, Middeke and colleagues highlight the poor outcome of the abnormal (17p) [abnl(17p)] subgroup of cytogenetically adverse-risk acute myeloid leukemia (AML) even after allogeneic hematopoietic stem cell transplantation (HSCT).

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The author declares no competing financial interests.

Figures

None
Schema for the physiological role of the p53 network in promoting genetic stability. WT p53 is normally targeted for proteasomal degradation by mdm2 but accumulates in states of cellular stress or damage. p53 transcriptionally regulates numerous target genes (including p21) as well as interacts directly with other proteins to either quarantine the cell for repair or condemn it to die. Professional illustration by Marie Dauenheimer.
See this image and copyright information in PMC

Comment on

References

    1. Middeke JM, Fang M, Cornelissen JJ, et al. Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Blood. 2014;123(19):2960–2967. - PubMed
    1. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059–2074. - PMC - PubMed
    1. Wong TN, Ramsingh G, Young A, et al. The role of early TP53 mutations on the evolution of therapy-related AML [abstract]. Blood. 2013;122(21) Abstract 5.
    1. Grossmann V, Schnittger S, Kohlmann A, et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood. 2012;120(15):2963–2972. - PubMed
    1. Bowen D, Groves MJ, Burnett AK, et al. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. Leukemia. 2009;23(1):203–206. - PubMed